EGFR and non-small cell lung carcinoma: Taking into account all in vitro data, compound 4 exerts selective and potent anti-NSCLC activity through the inhibition of EGFR TK, together with the induction of apoptosis, which may counter resistance to chemotherapy and radiotherapy.